VR Adviser, LLC Q4 2021 Filing
Filed February 14, 2022
Portfolio Value
$731.5B
Holdings
26
Report Date
Q4 2021
Filing Type
13F-HR
All Holdings (26 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | TILInstil Bio Inc | 6,865,076 | $117.5B | 16.06% | |
| 2 | ACRSAclaris Therapeutics Inc | 4,563,962 | $66.4B | 9.07% | |
| 3 | TVTXTravere Therapeutics Inc | 1,994,997 | $61.9B | 8.47% | |
| 4 | RLMDRelmada Therapeutics Inc | 2,270,072 | $51.1B | 6.99% | |
| 5 | GHRSGH Research PLC | 2,021,985 | $47.2B | 6.45% | |
| 6 | WHWKAadi Bioscience Inc | 1,529,402 | $36.9B | 5.05% | |
| 7 | VRDNViridian Therapeutics Inc | 1,852,919 | $36.6B | 5.01% | |
| 8 | MRNS*Marinus Pharmaceuticals Inc | 2,880,096 | $34.2B | 4.68% | |
| 9 | TCE2Celldex Therapeutics Inc | 865,116 | $33.4B | 4.57% | |
| 10 | 1T7Tricida Inc | 3,494,851 | $33.4B | 4.57% | |
| 11 | LIANYLianBio | 5,378,341 | $33.1B | 4.53% | |
| 12 | VTGNUSDVistaGen Therapeutics Inc | 16,047,286 | $31.3B | 4.28% | |
| 13 | 290AChinook Therapeutics Inc | 1,283,821 | $20.9B | 2.86% | |
| 14 | GRPHGraphite Bio Inc | 1,612,617 | $20.0B | 2.74% | |
| 15 | NUVLNuvalent Inc | 803,951 | $15.3B | 2.09% | |
| 16 | —Kinnate Biopharma Inc | 773,014 | $13.7B | 1.87% | |
| 17 | —Athira Pharma Inc | 1,000,000 | $13.0B | 1.78% | |
| 18 | CNTACentessa Pharmaceuticals PLC | 1,127,272 | $12.7B | 1.74% | |
| 19 | ATYRaTyr Pharma Inc | 1,565,000 | $11.7B | 1.60% | |
| 20 | COGTCogent Biosciences Inc | 1,088,817 | $9.3B | 1.28% | |
| 21 | —Affimed NV | 1,428,571 | $7.9B | 1.08% | |
| 22 | OLMAOlema Pharmaceuticals Inc | 816,651 | $7.6B | 1.04% | |
| 23 | CVRXCVRx Inc | 533,370 | $6.5B | 0.89% | |
| 24 | —Akoya Biosciences Inc | 400,000 | $6.1B | 0.84% | |
| 25 | CATBUSDAstria Therapeutics Inc | 538,999 | $2.9B | 0.40% | |
| 26 | CRVSCorvus Pharmaceuticals Inc | 250,000 | $603.0M | 0.08% |